Gilead Sciences (id:7062 GILD)
89.56 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 1:43:34 PM)
Exchange open, closes in 2 hours 16 minutes
About Gilead Sciences
Market Capitalization 110.46B
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Headquarters (address) |
333 Lakeside Drive Foster City 94404 CA United States |
| Phone | 650 574 3000 |
| Website | https://www.gilead.com |
| Employees | 18,000 |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | GILD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 62.07 - 98.90 |
| Market Capitalization | 110.46B |
| Dividend yield forward | 3.48 % |
| Dividend yield forward United States (ID:6, base:1863) | 4.22 % |
| P/E trailing | 984.78 |
| P/E forward | 11.93 |
| Price/Sale | 3.90 |
| Price/Book | 5.98 |
| Beta | 0.192 |
| EPS | 0.090 |
| EPS United States (ID:6, base:3389) | 24.33 |
Dividend growth streak
Gilead Sciences has raised their dividend 8.00 years in a row. This is above the 4.478497 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Gilead Sciences has raised their dividend 3.48 years in a row. This is below the 41113.895200 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Gilead Sciences has raised their dividend 3.32 years in a row. This is below the 24.014500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Gilead Sciences has raised their dividend 5.64 years in a row. This is below the 12.586200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Gilead Sciences has raised their dividend 3,400.00 years in a row. This is above the 146.967900 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
Gilead Sciences has raised their dividend 8.00 years in a row. This is above the 4.478497 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Gilead Sciences has raised their dividend 3.48 years in a row. This is below the 41113.895200 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Gilead Sciences has raised their dividend 3.32 years in a row. This is below the 24.014500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Gilead Sciences has raised their dividend 5.64 years in a row. This is below the 12.586200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Gilead Sciences has raised their dividend 3,400.00 years in a row. This is above the 146.967900 year average in the 'Drug Manufacturers General' industry